Tempus Priority Study: A Pan-tumor Observational Study

  • STATUS
    Recruiting
  • End date
    Oct 19, 2030
  • participants needed
    1000
  • sponsor
    Tempus Labs
Updated on 30 May 2022
cancer
hematologic malignancy

Summary

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Description

The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus. The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment.

Details
Condition Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Treatment Observation
Clinical Study IdentifierNCT05179824
SponsorTempus Labs
Last Modified on30 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Solid or hematologic malignancy
Willing and able to provide informed consent where required
Has received or will receive genomic profiling

Exclusion Criteria

Individuals without the capacity to consent
Prisoners at the time of enrollment
I/E criteria are specific for each cohort of Group 2 and available in the full
protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note